Under Armour: Demand Is Worse Than You Think, Hold Until Q2 Proves Otherwise

Under Armour has reported Q1 fiscal 2027, and the picture is clearer — and worse — than the headline numbers suggest.

Revenue fell 3% to $1.098 billion. North America, which represents roughly 56% of sales, declined 9%. E-commerce, a key growth channel for athletic apparel, slumped 12%. Footwear dropped 8%. Management cut the full-year guidance to a mid-single-digit revenue decline, and adjusted EPS guidance of roughly $0.10 is roughly half of what analysts had consensused before today's report.

The stock is down nearly 6% today, 9.5% over five days, and 16% over the last four months. It sits at $6.02, well below its 52-week high of $8.15 but up from a low of $4.13 earlier in the year.

A competitor headline says "challenging demand environment." That understates the situation. This is not a cyclical dip or a one-quarter wobble. North America has declined for five consecutive years. Under Armour is trading at 0.52 times trailing revenue — cheap enough to make investors think the market is overreacting. The question is whether the multiple is cheap because the business is a turnaround waiting to turn, or because the business has structural problems that a low multiple cannot fix overnight.

Here is the evidence for both sides.

What is going right — the case for the cheap valuation

Gross margin expanded 590 basis points to 54.1% in the quarter. Operating income was $47 million, and adjusted operating income was $52 million. North American segment operating margin jumped to 28.0% from 18.1% a year ago. On the surface, Under Armour is selling less but earning more per dollar — the hallmark of a business shedding low-margin revenue and protecting profitability.

The valuation is undeniably thin. At 0.52x sales and a $2.6 billion market cap, this is not a stock priced for growth. Compare that to Nike at 1.35x sales or Deckers at 2.4x sales. Under Armour is trading as if it is a distressed asset, not a branded athletic apparel company with $5 billion in annual revenue and global distribution.

The restructuring plan — eliminating roughly 25% of product lines and editing the portfolio toward higher-margin categories — is nearly complete. Management says it will be substantially done by December 31, 2026. That is four months away. The company has already spent $266 million of an expected $305 million total. The heavy lifting is behind them.

International growth provides some offset. EMEA grew 12% and Latin America grew 8% in the quarter. The brand still has demand outside North America.

What is going wrong — the reasons to be skeptical

Here is the critical detail that changes how you read the margin expansion: the entire 590-basis-point gross margin improvement came from refunds on IEEPA tariff costs that were expensed in the prior fiscal year. That is a one-time accounting recovery, not an operating improvement. Management's own full-year guidance allocates about 150 basis points of its projected margin expansion and roughly $70 million of its $96–$116 million operating income target to the same tariff refund mechanism. Strip out the refunds, and the organic margin story is a fraction of what the headline numbers suggest.

Revenue decline is broad and deep. Wholesale fell 2%, DTC fell 6%, and within DTC, owned stores dropped 3% while e-commerce collapsed 12%. Apparel, footwear, and accessories all declined. This is not a channel mix issue or a single-product weakness. The consumer is pulling back across every category and channel in Under Armour's most important market.

Inventory is rising despite declining revenue. Total inventory is $1.1 billion, down 3% year-over-year but up roughly 21% from the March 31, 2026 balance of $915 million. Inventory consumed $193.5 million of cash during the quarter. When sales are declining and inventory is climbing, the next logical pressure point is markdowns — which would hit gross margin precisely when the company is trying to defend it.

The guidance gap is the most telling signal. Adjusted EPS guidance of $0.08–$0.12 for the full year is roughly half of what analysts had consensused before today's report. When management cuts guidance by that magnitude, it is not a temporary miscalculation. It is an admission that the demand picture has worsened beyond what the street already assumed.

And the balance sheet is not pristine. Total debt stands at $3.0 billion against $309 million in cash, giving a debt-to-equity ratio of 84%. The company has $200 million outstanding on its $1.1 billion revolving credit facility. Free cash flow over the trailing twelve months is negative $81 million. Operating cash flow is negative $15 million. ROIC is -18%. ROE is -30%. This is a business consuming capital, not generating it.

The valuation test

Is 0.52x sales cheap enough? It is cheap compared to Nike and Deckers. It is cheap compared to Under Armour's own history. But cheap valuations on declining businesses are not bargains until the decline stops.

The business case for buying here requires two things to happen within the next four quarters: first, North America revenue decline has to narrow meaningfully from the 9% pace seen in Q1; and second, margin expansion has to come from pricing, mix, and lower discounting rather than tariff refunds that won't exist in fiscal 2028. The first signal of the first condition would come in the Q2 FY2027 report, likely in early November. If NA holds the line or declines at a much lower rate, the story changes. If it doesn't, the cheap valuation is exactly where it should be.

The tariff refund tailwind makes fiscal 2027 margins look better than the underlying business supports. That creates a trap: investors who see 54% gross margins and declare the business is turning around will find out in fiscal 2028 that those margins were propped up by a mechanism that won't repeat.

What changes the call

I would upgrade to Buy if Q2 shows North America revenue stabilizing — a decline of 2% or less, or flat-to-positive — and inventory levels begin to fall. That would signal demand has bottomed and the restructuring is working. Alternatively, if the company can produce organic gross margin expansion of 100+ basis points excluding tariff refunds, it would prove the pricing and discounting strategy is taking hold.

I would downgrade further if North America declines continue at double-digit rates, if inventory continues to build into Q2, or if management cuts guidance again. The current valuation gives the stock room to absorb some pain, but it does not immunize it.

Rating: Hold

The valuation is cheap, but not cheap enough to buy a business that is still deteriorating on revenue, burning cash on inventory, and relying on one-time tariff recoveries to look profitable. The restructuring plan completes in four months, and Q2 earnings in November will provide the first real test of whether demand has stabilized. Until then, the market's pessimism is justified — and the smart money waits for proof before stepping in.

The demand environment is not just challenging. It has been challenging for five consecutive years in the company's core market. A low multiple does not buy time. Evidence of inflection does.